Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22825416 | 0.78 | KDM4E (0.31) | ALDH1A1KDM4E | |
| SCHEMBL22309483 | 0.78 | ALDH1A1 (0.34) | TSHRALDH1A1ALOX15ESR1 | |
| SCHEMBL22309482 | 0.75 | SCN4A (0.32) | — | |
| SCHEMBL22309523 | 0.72 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL22309524 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL22309471 | 0.67 | LMNA (0.36) | TSHRALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL22309527 | 0.67 | KDM4E (0.42) | TSHRALDH1A1PPARAKDM4E | |
| SCHEMBL19431477 | 0.65 | ALDH1A1 (0.50) | BRD4TSHRALDH1A1PPARGPPARA | |
| SCHEMBL22309517 | 0.63 | — | — | |
| SCHEMBL27898746 | 0.62 | BRD4 (0.46) | BRD4ALDH1A1PPARGPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009854-A1 | A SERIES OF CATALYSTS FOR THE HYPERPOLARISATION OF SUBSTRATES | UNIVERSITY OF YORK (GB) | 2022-01-13 | — | — | US | disclosed |
| US-20210154333-A1 | POLARISATION TRANSFER VIA A SECOND METAL COMPLEX | UNIVERSITY OF YORK (GB) | 2021-05-27 | — | — | US | disclosed |
| US-20200397923-A1 | HYPERPOLARISATION IN AQUEOUS MEDIA VIA SABRE | UNIVERSITY OF YORK (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200246491-A1 | HyperPolarising Substrates Through Relayed Transfer Via Systems Containing Exchangeable Protons | UNIVERSITY OF YORK (GB) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009854-A1 | A SERIES OF CATALYSTS FOR THE HYPERPOLARISATION OF SUBSTRATES | SPR, YAP1, KRAS | BRD4 537/4885TSHR 1139/4885ALDH1A1 1891/4885 |
| US-20200246491-A1 | HyperPolarising Substrates Through Relayed Transfer Via Systems Containing Exchangeable Protons | TSPO, RHOT2, KRAS | BRD4 1764/4885TSHR 952/4885ALDH1A1 2261/4885 |
| US-20210154333-A1 | POLARISATION TRANSFER VIA A SECOND METAL COMPLEX | TSPO, SPR, TIMM50 | BRD4 2465/4885TSHR 2931/4885ALDH1A1 3970/4885 |
| US-20200397923-A1 | HYPERPOLARISATION IN AQUEOUS MEDIA VIA SABRE | KRAS, FH, HYOU1 | BRD4 1646/4885TSHR 1217/4885ALDH1A1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.